Skip to main content
Image
CKM logo reversed
CKM
Cardiology Vascular Medical Education
Register for free Log in
Cardiovascular • Kidney • Metabolic
Lifelong learning for healthcare professionals
CVRM banner
CVRM banner

Home

About

About Us Advisory Board

Topics

View AllChronic Kidney DiseaseDiabetesCardiovascular Co-morbiditiesMetabolic Dysfunction-associated Fatty Liver Disease (MAFLD)Obesity

Content type

Videos Articles Broadcasts Podcasts News

Faculty

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z View All

Events

Upcoming Events Radcliffe Events All Events

Resource Hubs

Inflammatory Risk in CVD Rise of CVRM
  • Content for healthcare professionals only
Image
CKM logo
Register for free Log in
Back to Main Menu

View all platforms

Cardiology Vascular CKM Medical Education
  • Content for healthcare professionals only

Breadcrumb

  • Home /
  • News Index

Latest News

hsCRP Improves CV Risk Prediction in Primary Prevention
Written by: Radcliffe CVRM
hsCRP Improves CV Risk Prediction in Primary Prevention
15 April 2026
Ez-PAVE: Lower LDL-C Target Reduces CV Events
Written by: Radcliffe CVRM
Ez-PAVE: Lower LDL-C Target Reduces CV Events
15 April 2026
SOUL: Oral Semaglutide Aids CV Risk in T2D
Written by: Radcliffe CVRM
SOUL: Oral Semaglutide Aids CV Risk in T2D
28 March 2026
GLP-1RAs Cut Cardiorenal Events in Type 1 Diabetes
Written by: Radcliffe CVRM
GLP-1RAs Cut Cardiorenal Events in Type 1 Diabetes
27 March 2026
Aldosteronism Linked to AF and Stroke Risk in Older Adults
Written by: Radcliffe CVRM
Aldosteronism Linked to AF and Stroke Risk in Older Adults
19 March 2026
Semaglutide May Aid Vascular Repair in High-Risk Patients
Written by: Radcliffe CVRM
Semaglutide May Aid Vascular Repair in High-Risk Patients
19 March 2026
Higher ARR Linked to AF and Stroke Risk in Older Adults
Written by: Radcliffe CVRM
Higher ARR Linked to AF and Stroke Risk in Older Adults
12 March 2026
Oral Orforglipron Superior to Semaglutide for T2D Control
Written by: Radcliffe CVRM
Oral Orforglipron Superior to Semaglutide for T2D Control
10 March 2026
Empagliflozin and Finerenone: Hyperkalemia Risk in CKD
Written by: Radcliffe CVRM
Empagliflozin and Finerenone: Hyperkalemia Risk in CKD
06 March 2026
Pelacarsen Cuts Lipoprotein Apheresis Need in CVD
Written by: Radcliffe CVRM
Pelacarsen Cuts Lipoprotein Apheresis Need in CVD
04 March 2026
  • Load More

External news

Written by: Medscape
Unexpected Results Lead to Questions on IVUS-Guided PCI
16 April 2026
Written by: Medscape
AF Screening May Flag Increased HF Risk
16 April 2026
Written by: Medscape
Graham Steell: Bedside Cardiology Before the ECG
16 April 2026
Written by: Medscape
Culture-Negative Endocarditis Shows Distinct Patterns
16 April 2026
Written by: Medscape
Adding Steroid Shows No Heart Benefit in Kawasaki Disease
16 April 2026
Written by: Cardiovascular Business
Long-term antidepressant use may increase risk of sudden cardiac death
15 April 2026
Written by: Cardiovascular Business
Stereotaxis to acquire robotic PCI company Robocath for up to $45M
15 April 2026
Written by: Cardiovascular Business
FDA links weight loss pill to ‘unexpected’ cardiovascular risks
15 April 2026
Written by: Medscape
EHRA 2026
15 April 2026
Written by: Cardiovascular Business
PFA associated with heightened stroke risk
15 April 2026
  • Load More

Footer Menu 1

  • About Us
  • Our team
  • Privacy
  • Terms & Conditions
  • Contact Us
  • Radcliffe Events
  • Radcliffe Group

Footer Menu 2

  • Authors A-Z
  • Image gallery
  • Industry Partners
  • Media Partners
  • Services
  • Promotional Opportunities

Quick Links 1

  • Heart Failure
  • Standards and Guidelines

Quick Links 2

  • Prevention and Chronic Conditions
  • Rise of CVRM
Register for FREE
CKM Logo

Copyright® 2026 Radcliffe Medical Media. All rights reserved.

Published content on this site is for information purposes and is not a substitute for professional medical advice. Where views/opinions are expressed, they are those of the author(s) and not of Radcliffe Medical Media.

Radcliffe Cardiology is part of Radcliffe Medical Media, an independent publisher and the Radcliffe Group Ltd. It is not affiliated with or is an agent of, the Oxford Heart Centre, the John Radcliffe Hospital or the Oxford University Hospitals NHS Foundation Trust group.